DexCom Introduces Registry to Monitor Outcomes of G6 System

DexCom, Inc. DXCM recently announced the first-ever registry committed toward keeping a track on the outcomes of patients and healthcare professionals using Continuous Glucose Monitoring (CGM) in hospitals to combat the COVID-19 pandemic.

Due to the urgency to preserve personal protective equipment, minimize potential hospital staff exposure to the virus and reduce the overall burden on nursing care, the Dexcom G6 CGM system has been made available to remotely monitor the glucose levels of all hospitalized patients during the pandemic. The decision was made in April based on feedback received from the FDA.

As part of exploratory studies over the last three years, it has been found that the use of Dexcom G6 system in hospital settings enhances glucose control without increasing the risk in hypoglycemia. A registry to study the experiences across many hospitals should prove highly beneficial.

Notably, Dexcom G6 uses a small, wearable sensor and transmitter to continuously read and send glucose levels wirelessly to a receiver or compatible smart device.

This development is expected to boost DexCom’s CGM portfolio.

About the CGM Registry

The registry can be accessed by healthcare providers using rtCGM in an inpatient or critical care setting. Providers will be able to upload information pertaining to the in-hospital care of each CGM patient, such as admissions, discharges, medications, status changes, diabetes history, comorbidities and more. The assimilated data will be deidentified and will not include any protected health information.

The data gathered through the registry will eventually be cross-referenced with patient CGM data and assessed by Dexcom for further product innovation or to include in future submissions for regulatory clearances to make rtCGM the prevalent standard of care in hospitals.


Recent Developments

In July 2020, Health Canada temporarily approved the adjunctive use of the Dexcom G6 CGM system by pregnant women afflicted with Type 1, Type 2, or gestational diabetes. This temporary expanded indication was authorized because of the proactive role Dexcom CGM can play in the treatment and alleviation of COVID-19 by significantly lessening the in-person interaction between pregnant women with diabetes and healthcare providers, thereby curbing potential exposure to the virus.

In June, DexCom announced that the Dexcom G6 CGM System has obtained CE Marking across Europe for being attached to the back of the upper arm, thereby offering patients more choice when it comes to comfortably wearing the device. This development is likely to strengthen the company’s presence in the lucrative glucose monitoring market and also boost product portfolio.

Market Prospects

Per a report by Grand View Research, the global CGM device market size was valued at $3.93 billion in 2019 and is estimated to witness a CAGR of 12.7% during the 2020-2027 period. Rising cases of diabetes and higher adoption of CGM devices have been driving the market.

Price Performance

Shares of this Zacks Rank #3 (Hold) company has rallied 149.2% in a year’s time compared with the industry’s growth of 19%.

Key Picks

A few better-ranked stocks from the broader medical space include OPKO Health OPK, Surmodics SRDX and Merit Medical Systems MMSI.

OPKO Health’s long-term earnings growth rate is estimated at 12%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2.

Merit Medical Systems’ long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Click to get this free report

DexCom, Inc. (DXCM): Free Stock Analysis Report

Surmodics, Inc. (SRDX): Free Stock Analysis Report

Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report

OPKO Health, Inc. (OPK): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More